Development and preclinical studies of ⁶⁴Cu-NOTA-pertuzumab F(ab')₂ for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.

ABSTRACT: We previously reported that microSPECT/CT imaging with ¹¹¹In-labeled pertuzumab detected decreased HER2 expression in human breast cancer (BC) xenografts in athymic mice associated with response to treatment with trastuzumab (Herceptin). Our aim was to extend these results to PET/CT by constructing F(ab')₂ of pertuzumab modified with NOTA chelators for complexing ⁶⁴Cu. The effect of the administered mass (5-200 µg) of ⁶⁴Cu-NOTA-pertuzumab F(ab')₂ was studied in NOD/SCID mice engrafted with HER2-positive SK-OV-3 human ovarian cancer xenografts. Biodistribution studies were performed in non-tumor bearing Balb/c mice to predict radiation doses to normal organs in humans. Serial PET/CT imaging was conducted on mice engrafted with HER2-posi

SUBMITTER: Lam K 

PROVIDER: S-EPMC5240646 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature